Paper Details

  1. Home
  2. Paper Details

Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.

Author: CammarotaGiovanni, GasbarriniAntonio, LopetusoLoris, PecereSilvia, PonzianiFrancesca Romana, ScaldaferriFranco

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Gut microbiota modulation by non-absorbable antibiotics is a potential therapeutic option for patients with Irritable Bowel Syndrome (IBS). This approach targets the multifactorial etiology of IBS, which includes alterations of intestinal motility and immunity, gut-brain interactions, and gut microbiota dysbiosis.
Paper Details　
Original Abstract of the Article :
Irritable bowel syndrome is a functional gastrointestinal disorder with a multifactorial etiology. Alterations of intestinal motility and immunity, gut-brain interactions, as well as gut microbiota dysbiosis contribute to the development of irritable bowel syndrome. Therefore, gut microbiota modulat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/14740338.2016.1186639

データ提供：米国国立医学図書館（NLM）

Rifaximin for Irritable Bowel Syndrome: A Safety Evaluation

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with a multifaceted etiology. This research explores the potential therapeutic role of rifaximin, a non-absorbable antibiotic, in managing IBS symptoms by modulating the gut microbiota.

Rifaximin: A Potential Therapeutic for Irritable Bowel Syndrome

The researchers provide a comprehensive overview of the complex factors contributing to IBS, including alterations in intestinal motility and immunity, gut-brain interactions, and gut microbiota dysbiosis. They highlight rifaximin as a promising therapeutic option for IBS, due to its ability to target the gut microbiota without being absorbed into the bloodstream.

The Importance of Gut Microbiota Modulation in IBS

This study underscores the growing understanding of the role of the gut microbiota in IBS and the potential benefits of targeting this ecosystem for therapeutic intervention. It’s like the delicate balance of an ecosystem in the desert – small changes can have a big impact.

Dr.Camel's Conclusion

This review provides a compelling argument for the potential therapeutic role of rifaximin in the management of IBS. The authors highlight the importance of gut microbiota modulation as a promising therapeutic strategy for this complex gastrointestinal disorder.

Date :
  1. Date Completed 2017-01-30
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27149541

DOI: Digital Object Identifier

10.1080/14740338.2016.1186639

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.